Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553649 | 0.79 | GID4 (0.44) | SLC6A2SLC6A3GSK3B | |
| SCHEMBL7812648 | 0.74 | SLC6A2 (0.51) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL6178580 | 0.74 | L3MBTL1 (0.53) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL2330365 | 0.74 | PRCP (0.37) | KCNH2GSK3B | |
| SCHEMBL30139646 | 0.74 | L3MBTL1 (0.53) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL1713225 | 0.74 | L3MBTL1 (0.53) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL2331878 | 0.73 | PRCP (0.40) | SLC6A2SLC6A3 | |
| SCHEMBL2708321 | 0.72 | SLC6A2 (0.58) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL22910976 | 0.72 | SLC6A2 (0.58) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL5729496 | 0.72 | SLC6A2 (0.54) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SLC6A2 3396/4885SLC6A3 1944/4885SLC6A4 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.